ReviewCurrent HIV/AIDS reports2013
Immunity and hepatitis C: a review.
Review in Current HIV/AIDS reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Learning from a rare phenomenon - spontaneous clearance of chronic hepatitis C virus post-liver transplant: A case report.World journal of hepatology · 2022Article
- Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000-2015): A Nationwide Study.Journal of clinical medicine · 2020Article
- Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.International journal of molecular sciences · 2018Review
- Hepatitis C virus infections and associated risk factors in patients with diabetes mellitus; case control study in North West Tigray, Ethiopia.BMC research notes · 2018Article
- Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.Immunological reviews · 2018Review
- Hepatitis C Virus Infection and Vaccine Development.Journal of clinical and experimental hepatology · 2018Review
- Effect of HIV/HCV Co-Infection on the Protease Evolution of HIV-1B: A Pilot Study in a Pediatric Population.Scientific reports · 2018Article
- Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.The Lancet. Infectious diseases · 2018Article
- Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.Virusdisease · 2016Article
- Progress in the development of vaccines for hepatitis C virus infection.World journal of gastroenterology · 2015Review
- Hepatitis C virus infection in the human immunodeficiency virus infected patient.World journal of gastroenterology · 2014Review
- Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.Human vaccines & immunotherapeutics · 2014Article
- Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea.Chinese medicine · 2013Article
- Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.Genes and immunityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatocellular carcinoma worldwide. Due to shared transmission routes, the prevalence of HCV is especially high among individuals infected with HIV. HIV uninfected individuals spontaneously clear HCV approximately 30 % of the time, while the rate of control in HIV infected individuals who subsequently acquire HCV is substantially lower. In addition, complications of HCV are more frequent in those with HIV infection, making liver disease the leading cause of non-AIDS-related death in HIV infected individuals. This review summarizes recent advances in understanding the role of the innate and adaptive immune responses to HCV in those with and without HIV. Further defining the interaction between hepatitis C and the host immune system will potentially reveal insights into HCV pathogenesis and the host's ability to prevent persistent infection, as well as direct the development of vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.